IL6R and systemic sclerosis: Importantly, gene expression analysis demonstrated augmentation of the M2 macrophage signature in the skin of patients with SSc, which was suppressed by anti-IL-6R mAb (tocilizumab) therapy associated with an improvement of fibrosis [38].